Huashan Hospital

Everest Medicines Announces Commercial Launch and First Prescription for XERAVA® in China

Retrieved on: 
Thursday, July 27, 2023
Vaccine, Neutropenia, VRE, Fungal infection, Eravacycline, Infection, Fever, New Drug Application, MRSA, Gram-negative bacteria, NDA, Urinary tract infection, First Affiliated Hospital of Xinjiang Medical University, Hematopoietic stem cell transplantation, Soochow University, Incidence, MDR, Radiation, HKEX, Patient, National Medical Products Administration, Huashan Hospital, Fudan University, IgA nephropathy, CRE, NMPA, Pharmaceutical industry, Mount Everest

SHANGHAI, July 26, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today XERAVA® (eravacycline) has been successfully launched in China with its first prescription issued at Huashan Hospital affiliated to Fudan University. The commercialization of XERAVA® in China marks Everest's transformation into a commercial-stage innovative biopharmaceutical company.

Key Points: 
  • "The commercialization of XERAVA® in China is a significant milestone for Everest as a company, as this marks the beginning of Everest as a commercial-stage biopharma company.
  • I want to thank everyone involved in bringing XERAVA® to a successful launch," said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines.
  • "After the commercial launch, we will accelerate patient access to XERAVA® with a lean commercial team, following a highly efficient commercial strategy.
  • The launch of eravacycline in China will help doctors tackle the challenges of clinical drug resistance."

Harbour BioMed Announces Biologics License Application Acceptance of Batoclimab for Treatment of Generalized Myasthenia Gravis by NMPA

Retrieved on: 
Thursday, June 29, 2023
Biologics license application, Therapy, Harbor, GMG, Clinical trial, Immunology, MD, Patient, National Medical Products Administration, Huashan Hospital, Fudan University, BioMed Central, Neurology, BLA, III, NMPA, Generic drug, Pharmaceutical industry

This is the first BLA accepted by NMPA since Harbour BioMed's establishment.

Key Points: 
  • This is the first BLA accepted by NMPA since Harbour BioMed's establishment.
  • "Anti-FcRn treatment is at the center of focus in gMG disease area.
  • Batoclimab is the first anti-FcRn treatment completed clinical development with positive results and confirmed efficacious and safe in Chinese gMG population.
  • "We are delighted that batoclimab has become our first BLA successfully accepted by the NMPA demonstrating our strong R&D capability.

Delivery of 170,000 Bottles of Azvudine Tablets During Spring Festival to Help Rural Areas Weather the Epidemic

Retrieved on: 
Tuesday, January 31, 2023
The Spring Festival, United Front Work Department, Indian Express Limited, Fever, Fudan University, Q&A, Tibet Autonomous Region, Hospital, Power Construction Corporation of China, Infection, Central Committee of the Chinese Communist Party, Commercial bank, Health, Medicine, Volunteering, New Year, The Good Doctor, Weather, Atmosphere, Assistant, The Bund Finance Center, Collaborative Project to Increase Production of Rural Doctor, Mahidol University, Tablet, SF Express, Chinese New Year, Ruijin Hospital, Consultant, CO-oximeter, Huashan Hospital, Spring Festival, City of Hope National Medical Center, Fosun Pharma, Industrial and Commercial Bank of China, COVID-19, China Institute for Innovation and Development Strategy, Negotiation, Industrial, Cough, City, Pharmaceutical industry, Fosun International, Azvudine

First, how to deliver materials to the grassroots during the peak-travel period of Spring Festival?

Key Points: 
  • First, how to deliver materials to the grassroots during the peak-travel period of Spring Festival?
  • While negotiating cooperation with SF Express, Fosun Foundation urgently recruited nearly a hundred employee volunteers within Fosun and its subsidiaries.
  • Coordinating with their plan of returning home during the Spring Festival, the volunteers personally delivered medication to the donated counties.
  • We hope play its due role in the revitalization of Chinese rural areas and the construction of a healthy China."

CGTN: New Approaches: Why China is easing its COVID-19 curbs now

Retrieved on: 
Tuesday, December 20, 2022
Death, World Health Organization, Vaccination, Severe acute respiratory syndrome coronavirus 2, Nature, Patient, Mutation, Respiratory disease, Laboratory, Hainan Medical University, Science Advances, COVID, National Institutes of Health, Routing protocol, Disease, University, Hong Kong residents, Alpha, COVID-19, Chinese Center for Disease Control and Prevention, Infection, Social mobility, Center for Infectious Disease Research and Policy, Virology, Mouse, Fudan University, Diagnosis, Economic development, Gamma, Sun, National Health Commission, Ageing, Virulence, Huashan Hospital, Animal, Pharmaceutical industry, Vaccine, Delta, Omicron

By November when China announced its new policies to relax a series of stringent measures meant to monitor and cut the spread of COVID-19, the country had reported over 5,000 deaths caused by this virus.

Key Points: 
  • By November when China announced its new policies to relax a series of stringent measures meant to monitor and cut the spread of COVID-19, the country had reported over 5,000 deaths caused by this virus.
  • The low death toll, out of a population of 1.4 billion, did not come easily.
  • As many countries tried and gave up stricter measures one after another in the past three years, China didn't follow.
  • Data showed that Omicron replicates to lower levels than the Delta in rhesus macaques, resulting in reduced clinical disease.

CGTN: New Approaches: Why China is easing its COVID-19 curbs now

Retrieved on: 
Tuesday, December 20, 2022
Death, World Health Organization, Vaccination, Severe acute respiratory syndrome coronavirus 2, Nature, Patient, Mutation, Respiratory disease, Laboratory, Hainan Medical University, Science Advances, COVID, National Institutes of Health, Routing protocol, Disease, University, Hong Kong residents, Alpha, COVID-19, Chinese Center for Disease Control and Prevention, Infection, Social mobility, Center for Infectious Disease Research and Policy, Virology, Mouse, Fudan University, Diagnosis, Economic development, Gamma, Sun, National Health Commission, Ageing, Virulence, Huashan Hospital, Animal, Pharmaceutical industry, Vaccine, Delta, Omicron

By November when China announced its new policies to relax a series of stringent measures meant to monitor and cut the spread of COVID-19, the country had reported over 5,000 deaths caused by this virus.

Key Points: 
  • By November when China announced its new policies to relax a series of stringent measures meant to monitor and cut the spread of COVID-19, the country had reported over 5,000 deaths caused by this virus.
  • The low death toll, out of a population of 1.4 billion, did not come easily.
  • As many countries tried and gave up stricter measures one after another in the past three years, China didn't follow.
  • Data showed that Omicron replicates to lower levels than the Delta in rhesus macaques, resulting in reduced clinical disease.

CGTN: 'New Approaches': Hospitals gear up to prioritize COVID-19 patients

Retrieved on: 
Wednesday, December 14, 2022
Hospital, Omicron, Shanghai Media Group, National Health Commission, ICU, CGTN, Fudan University, Patient, Huashan Hospital, City, Relaxation, Bed, COVID-19, Panic, Quarantine, National Association Medical Staff Services, Bureau, Health insurance, Animal, Pharmaceutical industry, Medicine, Vaccine

The measures require enhancing medical resources to prioritize COVID-19 patients.

Key Points: 
  • The measures require enhancing medical resources to prioritize COVID-19 patients.
  • To avoid panic and a squeeze on medical resources, local governments and hospitals are upgrading existing temporary hospitals, adding ICU beds and better distributing medical resources.
  • China built temporary hospitals to receive and treat COVID-19 patients with mild symptoms and cut off the spread of the virus.
  • "We have set up different areas and provided different channels for different groups of patients to ensure all the patients can receive medical care timely.

CGTN: 'New Approaches': Hospitals gear up to prioritize COVID-19 patients

Retrieved on: 
Wednesday, December 14, 2022
Hospital, Omicron, Shanghai Media Group, National Health Commission, ICU, CGTN, Fudan University, Patient, Huashan Hospital, City, Relaxation, Bed, COVID-19, Panic, Quarantine, National Association Medical Staff Services, Bureau, Health insurance, Animal, Pharmaceutical industry, Medicine, Vaccine

The measures require enhancing medical resources to prioritize COVID-19 patients.

Key Points: 
  • The measures require enhancing medical resources to prioritize COVID-19 patients.
  • To avoid panic and a squeeze on medical resources, local governments and hospitals are upgrading existing temporary hospitals, adding ICU beds and better distributing medical resources.
  • China built temporary hospitals to receive and treat COVID-19 patients with mild symptoms and cut off the spread of the virus.
  • "We have set up different areas and provided different channels for different groups of patients to ensure all the patients can receive medical care timely.

Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China

Retrieved on: 
Tuesday, August 9, 2022
FDA, Proteolysis targeting chimera, CEO, CDE, Kintore, Northern Territory, Breast, Technology, Patient, COVID-19, PROTAC, Prostate, Hair loss, Data analysis, HKEX, Pi, Acne, Fudan University, Safety, AGA, US Foods, Huashan Hospital, AR, Pharmacokinetics, Hair, Pharmaceutical industry, Chimera

The leading principal investigators (leading PIs) of the phase I clinical trial are Professor Zhang Jing and AssociateProfessor Wu Xiaojie from Huashan Hospital affiliated to Fudan University.

Key Points: 
  • The leading principal investigators (leading PIs) of the phase I clinical trial are Professor Zhang Jing and AssociateProfessor Wu Xiaojie from Huashan Hospital affiliated to Fudan University.
  • Dr. Youzhi Tong, founder, Chairman, and CEO of Kintor Pharma, commented, "Both indications of AGA and acne have great unmet clinical needs.
  • As the world's first company to develop a topical AR-PROTAC compound, Kintor is currently conducting phase I clinical trials of GT20029 in China and the United States.
  • In July 2021, Kintor announced the dosing of first batch of subjects in its China phase I clinical trial of GT20029.In February 2022,Kintor announced the dosing of first subjectin its USphase I clinical trial of GT20029.